Skip to content

Author

F. Stölzel

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Lung cancer after allogeneic hematopoietic stem cell transplantation.

INTRODUCTION Long-term outcomes of allogeneic hematopoietic cell transplantation (HCT) are improving, increasing the relevance of secondary malignancies, including lung cancer. The clinical utility of immune checkpoint inhibitors (ICIs) in this setting remains unclear and concerns regarding graft-versus-host disease (G...

M. Rost, C. Wehr, Miriam Mozaffari Jovein et al. · 0 citations
Open access Sep 2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its clinical impact remains un...

M. Wesener, U. Demel, T. Pabst et al. · 0 citations
Open access Aug 2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.

A. O. Saidy, B. Altmann, P. van Heteren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.